A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of B001 in Subjects With Aquaporin-4 Antibody (AQP4-IgG) Positive Neuromyelitis Optic Spectrum Disorder (NMOSD)
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs B 001 (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 27 Jan 2025 Planned End Date changed from 15 Dec 2024 to 15 Dec 2025.
- 27 Jan 2025 Planned primary completion date changed from 15 Dec 2024 to 15 Dec 2025.
- 11 May 2024 Planned primary completion date changed from 15 Apr 2024 to 15 Dec 2024.